Grace Dy, MD, medical oncology, Roswell Park Comprehensive Cancer Center, discusses the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) with 

The phase 1/2 CodeBreak 100 trial (NCT03600883) investigated sotorasib in pretreated patients with 

At 2 years of follow-up, which included an additional 48 patients from a phase 1 cohort, the updated objective response rate was about 41%, which fell within the expected range based on initial data, Dy says. Additionally, the median progression-free survival was about 6 months, Dy explains.

The updated results also examined patients who achieved responses during the initial findings, Dy explains. The analysis showed that about 51% of initial responders remained in response for 12 months or longer, and the median duration of response in these patients was 12.3 months, Dy concludes.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

AACR Annual Meeting

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.


Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC